New Released Information About the Additional Medicare Coverages for Leqembi
Dr. Keith Vossel, neurologist and Director of the Easton Center, was quoted in a Boston Globe’s STAT News article regarding physicians and patients showing interest in learning more about the new Alzheimer’s treatment, Leqembi.
https://epaper.bostonglobe.com/infinity/article_popover_share.aspx?guid=4db484fb-f048-4c14-8be9-607b3be6c8c0
Lecanemab, the New FDA-approved Drug for Patients with Early Alzheimer’s Disease (Segment 2 of 2)
Watch Dr. Keith Vossel's live interview on July 7th, with KCAL-LA Morning News, about the benefits of the treatment, possible side effects, and expected out-of-pocket costs with CMS coverage for patients eligible for Leqembi, a fully FDA-approved Alzheimer’s drug.
https://www.youtube.com/watch?v=NTpY3Qj2rc4
Lecanemab, the New FDA-approved Alzheimer's Drug - What to Know
Watch Dr. Keith Vossel's live interview with Marla Tellez on July 7th, FOX 11 News LA, about the FDA’s full approval of Alzheimer’s drug, Lecanemab, who is eligible, the treatment benefits, side effects, and expected costs with Medicare coverage.
https://www.youtube.com/watch?v=vh2Gz2oUlI8
Future Data Will Determine the Effectiveness of the New Alzheimer’s Drug
Dr. Keith Vossel, Neurologist and Director of the Easton Center, was quoted in a San Francisco Chronicle July 7th article about more observations and real-world data needed to determine the effectiveness of the newly approved Alzheimer’s drug, Leqembi.
https://www.sfchronicle.com/health/article/newly-approved-alzheimer-s-drug-leqembi-means-18188387.php
What Families Can Expect with the New FDA-Approved Alzheimer’s Medication, Leqembi
Watch Dr. Keith Vossel’s exclusive live interview with KNBC-LA, NBC Channel 4 News, about the FDA’s full approval of the Alzheimer’s drug, Lecanemab, marketed as Leqembi, and what it means for families with loved ones in the early stages of Alzheimer’s disease.
https://mms.tveyes.com/MediaCenterPlayer.aspx?u=aHR0cDovL21lZGlhY2
VudGVyLnR2ZXllcy5jb20vZG93bmxvYWRnYXRld2F5LmFzcHg%2FVXNlc
klEPTMzMzAxNiZNRElEPTE5ODMzNTcyJk1EU2VlZD02MjI5JlR5cGU9
TWVkaWE%3D
Lecanemab, the New FDA-approved Drug for Patients with Early Alzheimer’s Disease (Segment 1 of 2)
Watch Dr. Keith Vossel's live interview on July 6th, with KCAL-LA Evening News, about the benefits of the treatment, possible side effects, and expected out-of-pocket costs with CMS coverage for patients eligible for Leqembi, a fully FDA-approved Alzheimer’s drug.
https://www.youtube.com/watch?v=FSw1DtK6TzY
What’s Next for Leqembi After A Full Approval by the FDA
Listen to Dr. Keith Vossel’s exclusive interview with KNX News Radio, aired on July 6, 2023, about the FDA’s full approval of the first-in-class Alzheimer’s drug, Lecanemab, for people with early stages of Alzheimer’s disease; studies showed it to slow progression in cognitive decline.
https://omny.fm/shows/knxam-on-demand/fda-approves-new-alzheimers-drug
Heavy Alcohol Intake May Worsen Cognitive Decline in Alzheimer’s Disease
Dr. Keith Vossel, Director of the Easton Center, was interviewed by Medical News Today and commented on recent Alzheimer’s model research that suggested long-term excessive intake of alcohol can accelerate cognitive decline.
https://www.medicalnewstoday.com/articles/alcohol-overuse-may-speed-up-the-progression-of-alzheimers-disease
Recent Paper Suggests That a New Blood Biomarker of Abnormal Astrocytes May Help Predict Alzheimer's
Dr. Keith Vossel, Director of the Easton Center, was interviewed by Medical News Today about his viewpoint on a recent paper, which suggested that early detection of abnormal astrocytes could potentially predict the development of Alzheimer’s.
https://www.medicalnewstoday.com/articles/alzheimers-new-blood-biomarker-could-predict-risk-of-cognitive-decline#Implications-for-future-clinical-trial-development
Genetic Testing for Frontotemporal Dementia
Dr. Keith Vossel, Neurologist and Director of the Easton Center, was interviewed by DailyMail about some of the behaviors and emotional changes that patients and caregivers face with frontotemporal dementia, typically before the age of 60.
https://www.dailymail.co.uk/health/article-12111665/Knowledge-power-Healthy-Iowa-woman-27-told-95-chance-developing-dementia.html
Good results from Alzheimer's drug trial seen as 'potentially very important'
MarketWatch interviewed Dr. Keith Vossel about the results of the Phase 3 trial of Alzheimer's drug, donanemab.
https://www.marketwatch.com/story/eli-lillys-positive-results-from-a-alzheimers-trial-seen-as-potentially-very-important-53e008a1
New study suggests that a catheter ablation for Afib could reduce risk of cognitive decline
Dr. Keith Vossel, Neurologist and Director of the Mary S. Easton Center for Alzheimer’s Research and Care at UCLA, was interviewed by Healthline on April 20, 2023, warning study participants to take precautions when considering a catheter ablation procedure to reduce the risk of developing dementia.
https://www.healthline.com/health-news/this-minimally-invasive-treatment-for-afib-may-reduce-dementia-risk#Safer-technology-may-expand-options
What is Unique About the New Alzheimer's Medication?
Gilbert Cordova with ABC10 interviewed Dr. Keith Vossel about the uniqueness of Alzheimer’s new medication, lecanemab, which received accelerated approval by the FDA in early January 2023.
https://www.abc10.com/article/entertainment/television/programs/to-the-point/california-man-shares-how-new-medication-can-impact-the-future-of-alzheimers-disease-care/103-5aa17097-e592-4194-b363-5055464609ef
Dr. Vossel's Gives His Input on Bruce Willis' FTD Diagnosis
Daily Mail interviewed Dr. Keith Vossel for input on Bruce Willis’ FTD diagnosis and the potential impact on language, personality, and movement. Dr. Vossel discussed clinical studies looking into FTD.
https://www.dailymail.co.uk/health/article-11763727/Experts-fear-Bruce-Willis-FTD-diagnosis-rob-personality.html
New Alzheimer's Drug Given Accelerated Approval
Dr. Keith Vossel shares his thoughts on the FDA's accelerated approval of lecanemab with the Daily Mail.
https://www.dailymail.co.uk/health/article-11607771/US-country-world-approve-gamechanger-Alzheimers-drug-lecanemab.html
Axonal Swelling in Alzheimer’s Disease and New Tests May Improve the Certainty of Alzheimer’s Diagnosis
Dr. Keith Vossel was interviewed by Healthline about axonal spheroids in Alzheimer’s disease and a new urine test for Alzheimer’s that can improve diagnostic certainty.
https://www.healthline.com/health-news/alzheimers-disease-swelling-may-be-root-cause-new-drug-may-slow-progression
Eisai’s Approach To the New Alzheimer’s Drug
Financial Times interviewed Dr. Keith Vossel about his perceptions of treating Alzheimer’s patients with lecanemab.
https://www.ft.com/content/92e4a6d2-00fb-4b5d-9b2f-e8d5d97529a3
Can the New Alzheimer’s Drug Slow the Progression of the Disease?
Dr. Keith Vossel discussed the risks and benefits of lecanemab on CBC News on November 30th
https://www.cbc.ca/player/
The Risk and Benefits of the New Alzheimer’s Drug
Dr. Keith Vossel’s interview with Jane King from Nasdaq was featured on WISHTV.com, Wednesday’s Business Headlines, on November 30th about who may benefit from the lecanemab clinical trial study. https://www.wishtv.com/news/business/wednesdays-business-headlines-217/
Dr. Vossel Discussed the Work of the Easton Center on "Radio Night Live" AM970 in NY
Listen to Dr. Keith Vossel's interview with Kevin McCullough, New York's "Radio Night Live" AM970, on July 13, 2022, discussing the causes and risk factors of Alzheimer's disease and the work of the Easton Center in conducting clinical trials and research to find treatments.
Part 1:
https://eastonad.ucla.edu/images/media/Dr_Vossel_Pt-1_RNL_WNYM_Seg-2_7-13-22.mp3
Part 2:
https://eastonad.ucla.edu/images/media/Dr_Vossel_Pt-2_RNL_WNYM_Seg-3_7-13-22.mp3
Part 3:
https://eastonad.ucla.edu/images/media/Dr_Vossel_Pt-3_RNL_WNYM_Seg-4_7-13-22.mp3
Alzheimer's and Brain Awareness Month
Dr. Keith Vossel's exclusive interview with Alex Cohen about Alzheimer’s and Brain Awareness Month aired on Tues, June 28, 2022, around 8:40 PM, Spectrum News 1 SoCal Inside the Issues.
@SpecNews1SoCal, #BrainAwareness
https://eastonad.ucla.edu/images/SPECNEWS1_06-28-2022_20.43.12.mp4
Dr. Vossel's Op-Ed in the L.A. Times: Did aphasia influence Bruce Willis’ career decisions? Every case is unique
https://www.latimes.com/opinion/story/2022-03-31/bruce-willis-aphasia-brain-disorder-retirement
Dr. Vossel was interviewed for USA Today article, “Report: Up to 18% of adults over 60 have early stages of memory loss, cognitive problems.”
https://www.usatoday.com/story/news/health/2022/03/15/early-dementia-sign-report-shows-memory-loss-more-older-adults/7034266001/
Dr. Vossel's Op-Ed in the L.A. Times: The first treatment for Alzheimer's taught us some hard lessons
Phase 2a clinical trial published in JAMA Neurology. Low doses of an inexpensive and widely available antiseizure drug improves learning and memory and executive function in AD patients with epileptic activity
Links:
